Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company, has announced the publication of a new research study investigating the role of immune dysfunction in Parkinson's Disease $(PD)$. This study, partially funded by Coya and led by scientific advisors Dr. Aaron Thome and Dr. Stanley H. Appel, explores the correlation between inflammation, oxidative stress, and the progression of PD. Published in the journal Frontiers of Immunology, the research highlights the upregulation of pro-inflammatory cytokine transcripts such as interleukin 6 (IL-6) and interleukin 1 beta (IL-1b) in PD patients, with increased expression correlating to advanced PD stages. These findings support the dual immunomodulatory approach of Coya's investigational therapy, COYA 302, which aims to enhance regulatory T cell function and suppress inflammation. Results from this cross-sectional study have already been presented in the publication.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。